IL1B and tuberculosis: Clinical experience with canakinumab and anakinra provides comforting real‐world evidence that the risk of Mycobacterium tuberculosis reactivation and tuberculosis development is significantly lower with IL‐1‐targeted biologics compared to TNF‐α inhibitors, but it is evident that chronic IL‐1 blockade does increase risk of opportunistic infections of the upper airways along with some evidence of increased urinary tract infections with Escherichia coli and Streptococci.102, 111